{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,20]],"date-time":"2026-01-20T11:48:16Z","timestamp":1768909696085,"version":"3.49.0"},"reference-count":73,"publisher":"MDPI AG","issue":"4","license":[{"start":{"date-parts":[[2024,2,7]],"date-time":"2024-02-07T00:00:00Z","timestamp":1707264000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>A set of nine derivatives, including five brominated compounds, was synthesized and the structures of these novel compounds were confirmed using 1H and 13C NMR as well as ESI MS spectra. These compounds were tested on four different cancer cell lines, chronic myelogenous leukemia (K562), prostate cancer (PC3), colon cancer (SW620), human kidney cancer (Caki 1), and on healthy human keratocytes (HaCaT). MTT results reveal that two newly developed derivatives (6 and 8) exhibit selective action towards K562 cells and no toxic effect in HaCat cells. The biological activity of these two most promising compounds was evaluated by trypan blue assay, reactive oxygen species generation, and IL-6 secretion. To investigate the proapoptotic activity of selected compounds, the two following types of tests were performed: Annexin V Apoptosis Detection Kit I and Caspase-Glo 3\/7 assay. The studies of the mechanism showed that both compounds have pro-oxidative effects and increase reactive oxygen species in cancer cells, especially at 12 h incubation. Through the Caspase-Glo 3\/7 assay, the proapoptotic properties of both compounds were confirmed. The Annexin V-FITC test revealed that compounds 6 and 8 induce apoptosis in K562 cells. Both compounds inhibit the release of proinflammatory interleukin 6 (IL-6) in K562 cells. Additionally, all compounds were screened for their antibacterial activities using standard and clinical strains. Within the studied group, compound 7 showed moderate activity towards Gram-positive strains in antimicrobial studies, with MIC values ranging from 16 to 64 \u00b5g\/mL.<\/jats:p>","DOI":"10.3390\/ijms25041999","type":"journal-article","created":{"date-parts":[[2024,2,7]],"date-time":"2024-02-07T03:47:09Z","timestamp":1707277629000},"page":"1999","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["New Derivatives of 1-(3-Methyl-1-Benzofuran-2-yl)Ethan-1-one: Synthesis and Preliminary Studies of Biological Activity"],"prefix":"10.3390","volume":"25","author":[{"given":"Mariola","family":"Napi\u00f3rkowska","sequence":"first","affiliation":[{"name":"Chair and Department of Biochemistry, Medical University of Warsaw, 1 Banacha Str., 02-097 Warsaw, Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pratheeba","family":"Kumaravel","sequence":"additional","affiliation":[{"name":"Chair and Department of Biochemistry, Medical University of Warsaw, 1 Banacha Str., 02-097 Warsaw, Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-9848-4972","authenticated-orcid":false,"given":"Mithulya","family":"Amboo Mahentheran","sequence":"additional","affiliation":[{"name":"Chair and Department of Biochemistry, Medical University of Warsaw, 1 Banacha Str., 02-097 Warsaw, Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ewelina","family":"Kiernozek-Kali\u0144ska","sequence":"additional","affiliation":[{"name":"Department of Immunology, Faculty of Biology, University of Warsaw, 1 Miecznikowa Str., 02-096 Warsaw, Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1318-1018","authenticated-orcid":false,"given":"Emilia","family":"Grosicka-Maci\u0105g","sequence":"additional","affiliation":[{"name":"Department of Biochemistry and Laboratory Diagnostic, Collegium Medicum Cardinal Stefan Wyszy\u0144ski University, Kazimierza W\u00f3ycickiego 1 Str., 01-938 Warsaw, Poland"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2024,2,7]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1056\/NEJM199907153410306","article-title":"The biology of chronic myeloid leukemia","volume":"341","author":"Faderl","year":"1999","journal-title":"N. Engl. J. Med."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1111\/ijlh.13135","article-title":"How I investigate acute myeloid leukemia","volume":"42","author":"Narayanan","year":"2020","journal-title":"Int. J. Lab. Hematol."},{"key":"ref_3","first-page":"357027","article-title":"Imatinib: A breakthrough of targeted therapy in cancer","volume":"2014","author":"Iqbal","year":"2014","journal-title":"Chemother. Res. Pract."},{"key":"ref_4","first-page":"596483","article-title":"Therapy of chronic myeloid leukemia: Twilight of the imatinib era?","volume":"2014","author":"Trela","year":"2014","journal-title":"ISRN Oncol."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1056\/NEJMra013339","article-title":"Imatinib mesylate\u2014A new oral targeted therapy","volume":"346","author":"Savage","year":"2002","journal-title":"N. Engl. J. Med."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1124\/pr.55.3.4","article-title":"Specific targeted therapy of chronic myelogenous leukemia with imatinib","volume":"55","author":"Deininger","year":"2003","journal-title":"Pharmacol. Rev."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1002\/phar.1266","article-title":"Treatment-, patient-, and disease-related factors and the emergence of adverse events with tyrosine kinase inhibitors for the treatment of chronic myeloid leukemia","volume":"33","author":"Irvine","year":"2013","journal-title":"Pharmacotherapy"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1007\/s12012-007-0015-3","article-title":"Role of anthracyclines in the era of targeted therapy","volume":"7","author":"Coronado","year":"2007","journal-title":"Cardiovasc. Toxicol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1016\/j.biopha.2017.11.040","article-title":"Alterations of biomechanics in cancer and normal cells induced by doxorubicin","volume":"97","author":"Fraczkowska","year":"2018","journal-title":"Biomed. Pharmacother."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.gde.2005.11.002","article-title":"Targeted CML therapy: Controlling drug resistance, seeking cure","volume":"16","author":"Corbin","year":"2006","journal-title":"Curr. Opin. Genet. Dev."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1016\/S1470-2045(07)70342-X","article-title":"Part I: Mechanisms of resistance to imatinib in chronic myeloid leukaemia","volume":"8","author":"Apperley","year":"2007","journal-title":"Lancet Oncol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1116","DOI":"10.1016\/S1470-2045(07)70379-0","article-title":"Part II: Management of resistance to imatinib in chronic myeloid leukaemia","volume":"8","author":"Apperley","year":"2007","journal-title":"Lancet Oncol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"913","DOI":"10.7326\/0003-4819-145-12-200612190-00008","article-title":"New insights into the pathophysiology of chronic myeloid leukemia and imatinib resistance","volume":"145","author":"Kantarjian","year":"2006","journal-title":"Ann. Intern. Med."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"2029","DOI":"10.1158\/1535-7163.MCT-11-0745","article-title":"Bortezomib: Understanding the mechanism of action","volume":"10","author":"Piperdi","year":"2011","journal-title":"Mol. Cancer Ther."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"1794","DOI":"10.1002\/cncr.21414","article-title":"Proteasome inhibition and its clinical prospects in the treatment of hematologic and solid malignancies","volume":"104","author":"Ludwig","year":"2005","journal-title":"Cancer"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"2609","DOI":"10.1056\/NEJMoa030288","article-title":"A Phase 2 Study of Bortezomib in Relapsed, Refractory Myeloma","volume":"348","author":"Richardson","year":"2003","journal-title":"N. Engl. J. Med."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1002\/ptr.887","article-title":"Antiinflammatory activity of the antirheumatic herbal drug, gravel root (Eupatorium purpureum): Further biological activities and constituents","volume":"15","author":"Habtemariam","year":"2001","journal-title":"Phytother. Res."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1016\/S0031-9422(00)00225-9","article-title":"nor-Lignans from the leaves of Styrax ferrugineus (Styracaceae) with antibacterial and antifungal activity","volume":"55","author":"Pauletti","year":"2000","journal-title":"Phytochemistry"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1833","DOI":"10.1016\/S0960-894X(01)00319-5","article-title":"Design and synthesis of novel benzofurans as a new class of antifungal agents targeting fungal N-myristoyltransferase. Part 1","volume":"11","author":"Masubuchi","year":"2001","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1515\/znc-2002-7-828","article-title":"Aurones interfere with Leishmania major mitochondrial fumarate reductase","volume":"57","author":"Kayser","year":"2002","journal-title":"Z. Naturforsch C J. Biosci."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1016\/j.bmcl.2003.10.039","article-title":"4-Hydroxy-3-methyl-6-phenylbenzofuran-2-carboxylic acid ethyl ester derivatives as potent anti-tumor agents","volume":"14","author":"Hayakawa","year":"2004","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1517\/13543776.2013.801455","article-title":"Benzofuran derivatives: A patent review","volume":"23","author":"Dawood","year":"2013","journal-title":"Expert Opin. Ther. Pat."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1016\/j.ejmech.2014.11.039","article-title":"Bioactive Benzofuran derivatives: A review","volume":"97","author":"Khanam","year":"2015","journal-title":"Eur. J. Med. Chem."},{"key":"ref_24","doi-asserted-by":"crossref","unstructured":"Ma, Y., Zheng, X., Gao, H., Wan, C., Rao, G., and Mao, Z. (2016). Design, Synthesis, and Biological Evaluation of Novel Benzofuran Derivatives Bearing N-Aryl Piperazine Moiety. Molecules, 21.","DOI":"10.3390\/molecules21121684"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1080\/14756366.2020.1862101","article-title":"Novel oxindole\/benzofuran hybrids as potential dual CDK2\/GSK-3beta inhibitors targeting breast cancer: Design, synthesis, biological evaluation, and in silico studies","volume":"36","author":"Eldehna","year":"2021","journal-title":"J. Enzym. Inhib. Med. Chem."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"e2000006","DOI":"10.1002\/ardp.202000006","article-title":"Synthesis, cytotoxicity, and molecular docking of substituted 3-(2-methylbenzofuran-3-yl)-5-(phenoxymethyl)-1,2,4-oxadiazoles","volume":"353","author":"Mokenapelli","year":"2020","journal-title":"Arch. Pharm."},{"key":"ref_27","doi-asserted-by":"crossref","unstructured":"Jin, L.P., Xie, Q., Huang, E.F., Wang, L., Zhang, B.Q., Hu, J.S., Wan, D.C., Jin, Z., and Hu, C. (2020). Design, synthesis, and biological activity of a novel series of benzofuran derivatives against oestrogen receptor-dependent breast cancer cell lines. Bioorg. Chem., 95.","DOI":"10.1016\/j.bioorg.2020.103566"},{"key":"ref_28","doi-asserted-by":"crossref","unstructured":"Siddiqui, S.K., SahayaSheela, V.J., Kolluru, S., Pandian, G.N., Santhoshkumar, T.R., Dan, V.M., and Ramana, C.V. (2020). Discovery of 3-(benzofuran-2-ylmethyl)-1H-indole derivatives as potential autophagy inducers in cervical cancer cells. Bioorganic Med. Chem. Lett., 30.","DOI":"10.1016\/j.bmcl.2020.127431"},{"key":"ref_29","doi-asserted-by":"crossref","unstructured":"Li, Q., Jian, X.E., Chen, Z.R., Chen, L., Huo, X.S., Li, Z.H., You, W.W., Rao, J.J., and Zhao, P.L. (2020). Synthesis and biological evaluation of benzofuran-based 3,4,5-trimethoxybenzamide derivatives as novel tubulin polymerization inhibitors. Bioorg. Chem., 102.","DOI":"10.1016\/j.bioorg.2020.104076"},{"key":"ref_30","doi-asserted-by":"crossref","unstructured":"Qi, Z.Y., Hao, S.Y., Tian, H.Z., Bian, H.L., Hui, L., and Chen, S.W. (2020). Synthesis and biological evaluation of 1-(benzofuran-3-yl)-4-(3,4,5-trimethoxyphenyl)-1H-1,2,3-triazole derivatives as tubulin polymerization inhibitors. Bioorg. Chem., 94.","DOI":"10.1016\/j.bioorg.2019.103392"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1016\/j.ejmech.2017.05.017","article-title":"Novel 1-(7-ethoxy-1-benzofuran-2-yl) substituted chalcone derivatives: Synthesis, characterization and anticancer activity","volume":"136","author":"Coskun","year":"2017","journal-title":"Eur. J. Med. Chem."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"4737","DOI":"10.3390\/molecules15074737","article-title":"Synthesis and preliminary evaluation of the antimicrobial activity of selected 3-benzofurancarboxylic acid derivatives","volume":"15","author":"Kossakowski","year":"2010","journal-title":"Molecules"},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"115","DOI":"10.2174\/187152061501141204124709","article-title":"Synthesis and Cytotoxic Properties of Halogen and Aryl-\/Heteroarylpiperazinyl Derivatives of Benzofurans","volume":"15","author":"Krawiecka","year":"2015","journal-title":"Anti-Cancer Agents Med. Chem."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"375","DOI":"10.2174\/1871520619666181122123552","article-title":"Novel Benzo[B]Furans with Anti-Microtubule Activity Upregulate Expression of Apoptotic Genes and Arrest Leukemia Cells in G2\/M Phase","volume":"19","author":"Cieslak","year":"2019","journal-title":"Anti-Cancer Agents Med. Chem."},{"key":"ref_35","doi-asserted-by":"crossref","unstructured":"Napi\u00f3rkowska, M., Cie\u015blak, M., Ka\u017amierczak-Bara\u0144ska, J., Kr\u00f3lewska-Goli\u0144ska, K., and Nawrot, B. (2019). Synthesis of new derivatives of benzofuran as potential anticancer agents. Molecules, 24.","DOI":"10.3390\/molecules24081529"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/B978-0-323-98367-9.00006-8","article-title":"Methods and models for in vitro toxicity","volume":"Volume 2","author":"Gupta","year":"2022","journal-title":"Pharmacokinetics and Toxicokinetic Considerations"},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"A","DOI":"10.1002\/0471142735.ima03bs21","article-title":"Trypan Blue Exclusion Test of Cell Viability","volume":"21","author":"Strober","year":"1997","journal-title":"Curr. Protoc. Immunol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"A3","DOI":"10.1002\/0471142735.ima03bs111","article-title":"Trypan Blue Exclusion Test of Cell Viability","volume":"111","author":"Strober","year":"2015","journal-title":"Curr. Protoc. Immunol."},{"key":"ref_39","doi-asserted-by":"crossref","unstructured":"Ali, I., Rafique, R., Khan, K.M., Chigurupati, S., Ji, X., Wadood, A., Rehman, A.U., Salar, U., Iqbal, M.S., and Taha, M. (2020). Potent \u03b1-amylase inhibitors and radical (DPPH and ABTS) scavengers based on benzofuran-2-yl(phenyl)methanone derivatives: Syntheses, in vitro, kinetics, and in silico studies. Bioorg. Chem., 104.","DOI":"10.1016\/j.bioorg.2020.104238"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"1800128","DOI":"10.1002\/ardp.201800128","article-title":"Cytotoxicity of new pyridazin-3(2 H)-one derivatives orchestrating oxidative stress in human triple-negative breast cancer (MDA-MB-468)","volume":"351","author":"Bouchmaa","year":"2018","journal-title":"Arch. Pharm."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/j.pharep.2016.11.007","article-title":"A review on antioxidant potential of bioactive heterocycle benzofuran: Natural and synthetic derivatives","volume":"69","author":"Chand","year":"2017","journal-title":"Pharmacol. Rep."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"4098","DOI":"10.1182\/blood-2002-08-2512","article-title":"Free radical stress in chronic lymphocytic leukemia cells and its role in cellular sensitivity to ROS-generating anticancer agents","volume":"101","author":"Zhou","year":"2003","journal-title":"Blood"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"2663","DOI":"10.1182\/blood-2013-10-532200","article-title":"Mitochondrial metabolism contributes to oxidative stress and reveals therapeutic targets in chronic lymphocytic leukemia","volume":"123","author":"Jitschin","year":"2014","journal-title":"Blood"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"3945","DOI":"10.1111\/cas.15068","article-title":"Reactive oxygen species in cancer: Current findings and future directions","volume":"112","author":"Nakamura","year":"2021","journal-title":"Cancer Sci."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1016\/j.phrs.2015.06.013","article-title":"Mitochondrial ROS and cancer drug resistance: Implications for therapy","volume":"100","author":"Okon","year":"2015","journal-title":"Pharmacol. Res."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/j.molcel.2012.09.025","article-title":"Physiological Roles of Mitochondrial Reactive Oxygen Species","volume":"48","author":"Sena","year":"2012","journal-title":"Mol. Cell"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1042\/bj3130017","article-title":"Damage to DNA by reactive oxygen and nitrogen species: Role in inflammatory disease and progression to cancer","volume":"313","author":"Wiseman","year":"1996","journal-title":"Biochem. J."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1038\/nrd4002","article-title":"Modulation of oxidative stress as an anticancer strategy","volume":"12","author":"Gorrini","year":"2013","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"3015","DOI":"10.1182\/blood-2015-11-682906","article-title":"IL-4 enhances expression and function of surface IgM in CLL cells","volume":"127","author":"Blunt","year":"2016","journal-title":"Blood"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1016\/j.bcmd.2014.11.006","article-title":"IL-6, IL-10, c-Jun and STAT3 expression in B-CLL","volume":"54","author":"Antosz","year":"2015","journal-title":"Blood Cells Mol. Dis."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"1686","DOI":"10.1038\/leu.2016.356","article-title":"IL-10 production by CLL cells is enhanced in the anergic IGHV mutated subset and associates with reduced DNA methylation of the IL10 locus","volume":"31","author":"Drennan","year":"2017","journal-title":"Leukemia"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"13994","DOI":"10.1002\/jcp.28086","article-title":"Increased autocrine interleukin-6 production is significantly associated with worse clinical outcome in patients with chronic lymphocytic leukemia","volume":"234","author":"Wang","year":"2019","journal-title":"J. Cell. Physiol."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.cytogfr.2009.11.005","article-title":"Dangerous liaisons: STAT3 and NF-\u03baB collaboration and crosstalk in cancer","volume":"21","author":"Grivennikov","year":"2010","journal-title":"Cytokine Growth Factor Rev."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1089\/gtmb.2016.0036","article-title":"The Associations of IL-6, IFN-\u03b3, TNF-\u03b1, IL-10, and TGF-\u03b21 Functional Variants with Acute Myeloid Leukemia in Turkish Patients","volume":"20","author":"Nursal","year":"2016","journal-title":"Genet. Test. Mol. Biomark."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1016\/j.cyto.2012.12.023","article-title":"Cytokine profiles in acute myeloid leukemia patients at diagnosis: Survival is inversely correlated with IL-6 and directly correlated with IL-10 levels","volume":"61","author":"Bergua","year":"2013","journal-title":"Cytokine"},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.1182\/bloodadvances.2017007856","article-title":"Interleukin-6 levels predict event-free survival in pediatric AML and suggest a mechanism of chemotherapy resistance","volume":"1","author":"Stevens","year":"2017","journal-title":"Blood Adv."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1515\/hsz-2020-0196","article-title":"HDAC8 promotes daunorubicin resistance of human acute myeloid leukemia cells via regulation of IL-6 and IL-8","volume":"402","author":"Wu","year":"2021","journal-title":"Biol. Chem."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1515\/hsz-2020-0345","article-title":"JMJD3-regulated expression of IL-6 is involved in the proliferation and chemosensitivity of acute myeloid leukemia cells","volume":"402","author":"Xu","year":"2021","journal-title":"Biol. Chem."},{"key":"ref_59","first-page":"11","article-title":"Expression of interleukin 6 and its specific receptor by untreated and PMA-stimulated human erythroid and megakaryocytic cell lines","volume":"19","author":"Navarro","year":"1991","journal-title":"Exp. Hematol."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"3765","DOI":"10.1182\/blood.V95.12.3765.012k50_3765_3770","article-title":"Constitutive Stat3, Tyr705, and Ser727 phosphorylation in acute myeloid leukemia cells caused by the autocrine secretion of interleukin-6","volume":"95","author":"Schuringa","year":"2000","journal-title":"Blood"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"646628","DOI":"10.3389\/fphar.2021.646628","article-title":"Galangin Inhibits Gastric Cancer Growth through Enhancing STAT3 Mediated ROS Production","volume":"12","author":"Liang","year":"2021","journal-title":"Front. Pharmacol."},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"516","DOI":"10.1016\/j.ccell.2017.03.003","article-title":"Direct Pharmacological Targeting of a Mitochondrial Ion Channel Selectively Kills Tumor Cells In Vivo","volume":"31","author":"Leanza","year":"2017","journal-title":"Cancer Cell"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.canlet.2016.03.042","article-title":"Reactive oxygen species (ROS) and cancer: Role of antioxidative nutraceuticals","volume":"387","author":"Prasad","year":"2017","journal-title":"Cancer Lett."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"44879","DOI":"10.18632\/oncotarget.9821","article-title":"Mitochondrial dysfunction and oxidative stress in aging and cancer","volume":"7","author":"Kudryavtseva","year":"2016","journal-title":"Oncotarget"},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"83530","DOI":"10.18632\/oncotarget.13171","article-title":"A novel benzofuran derivative, ACDB, induces apoptosis of human chondrosarcoma cells through mitochondrial dysfunction and endoplasmic reticulum stress","volume":"7","author":"Su","year":"2016","journal-title":"Oncotarget"},{"key":"ref_66","doi-asserted-by":"crossref","unstructured":"Liu, J.-F., Chen, C.-Y., Chen, H.-T., Chang, C.-S., and Tang, C.-H. (2016). BL-038, a Benzofuran Derivative, Induces Cell Apoptosis in Human Chondrosarcoma Cells through Reactive Oxygen Species\/Mitochondrial Dysfunction and the Caspases Dependent Pathway. Int. J. Mol. Sci., 17.","DOI":"10.3390\/ijms17091491"},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1016\/j.bbabio.2008.03.024","article-title":"Regulation of apoptosis by the redox state of cytochrome c","volume":"1777","author":"Brown","year":"2008","journal-title":"Biochim. Biophys. Acta (BBA)\u2014Bioenerg."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1126\/science.1115035","article-title":"Caspases 3 and 7: Key mediators of mitochondrial events of apoptosis","volume":"311","author":"Lakhani","year":"2006","journal-title":"Science"},{"key":"ref_69","doi-asserted-by":"crossref","unstructured":"Brentnall, M., Rodriguez-Menocal, L., De Guevara, R.L., Cepero, E., and Boise, L.H. (2013). Caspase-9, caspase-3 and caspase-7 have distinct roles during intrinsic apoptosis. BMC Cell Biol., 14.","DOI":"10.1186\/1471-2121-14-32"},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"111810","DOI":"10.1016\/j.ejmech.2019.111810","article-title":"Anticancer and antimicrobial effects of novel ciprofloxacin fatty acids conjugates","volume":"185","author":"Chrzanowska","year":"2020","journal-title":"Eur. J. Med. Chem."},{"key":"ref_71","unstructured":"(2018). M7-A7: Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria That Grow Aerobically, Clinical and Laboratory Standards Institute (CLSI)."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"965","DOI":"10.2174\/138527209788680808","article-title":"Synthesis, Characterization and Physico-chemical Properties of New 2-(4-Arylpiperazine-1-yl)-1-(3-methylbenzofuran-2-yl)ethanoles as Potential Antihypertensive Agents","volume":"13","author":"Opatrilova","year":"2009","journal-title":"Curr. Org. Chem."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/978-1-4939-6960-9_1","article-title":"Basic Colorimetric Proliferation Assays: MTT, WST, and Resazurin","volume":"1601","author":"Prabst","year":"2017","journal-title":"Methods Mol. Biol."}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/25\/4\/1999\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T13:56:10Z","timestamp":1760104570000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/25\/4\/1999"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2,7]]},"references-count":73,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2024,2]]}},"alternative-id":["ijms25041999"],"URL":"https:\/\/doi.org\/10.3390\/ijms25041999","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,2,7]]}}}